Evidence map›Paper›PMID 37317810›Full record

Trial reportPediatrics2023

HPV16/18 Antibody Responses After a Single Dose of Nonavalent HPV Vaccine.

Yi Zeng, Anna-Barbara Moscicki, Heide Woo, Chiu-Hsieh Hsu, Troy J Kemp, Ligia A Pinto, Eva Szabo, Eileen Dimond, Julie Bauman, Vikrant V Sahasrabuddhe and 1 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yi Zeng *Department of Pediatrics.
Anna-Barbara Moscicki *Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
Heide WooDepartment of Pediatrics, University of California Los Angeles, Los Angeles, California.
Chiu-Hsieh HsuUniversity of Arizona Cancer Center, University of Arizona, Tucson, Arizona.
Troy J KempVaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Ligia A PintoVaccine, Immunity and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Eva SzaboDivision of Cancer Prevention, National Cancer Institute, Rockville, Maryland.
Eileen DimondDivision of Cancer Prevention, National Cancer Institute, Rockville, Maryland.
Julie BaumanUniversity of Arizona Cancer Center, University of Arizona, Tucson, Arizona.
Vikrant V Sahasrabuddhe *Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland.
H-H Sherry Chow *Department of Pediatrics, University of California Los Angeles, Los Angeles, California.
National Cancer Institute · USUniversity of California, Los Angeles · USFrederick National Laboratory for Cancer Research · USUniversity of Arizona · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P30 CA023074
6 · The paper itself

Abstract

objectivesA single dose of human papillomavirus (HPV) vaccine would simplify logistics and reduce costs of vaccination programs worldwide. We conducted a phase IIa trial to determine the stability of HPV type-specific antibody responses after a single dose of the nonavalent HPV vaccine, Gardasil9.

methodsTwo hundred-and-one healthy 9 to 11-year-old girls and boys were enrolled at 2 centers in the United States to receive a prime dose of the nonavalent vaccine at baseline, a delayed dose at month 24, and an optional third dose at month 30. Blood samples were collected to measure HPV type-specific antibodies at baseline and at 6, 12, 18, 24, and 30 months after the prime dose. The primary outcomes were serum HPV16 and HPV18 antibody responses.

resultsIn both girls and boys, geometric mean concentrations of HPV16 and HPV18 antibodies increased at 6 months, declined between months 6 to 12, and then remained stable and high (at 20- and 10-times those at baseline for HPV16 and HPV18, respectively) throughout months 12, 18, and 24 (prebooster) visits. Both HPV16 and HPV18 antibody responses demonstrated anamnestic boosting effect at 30-months after the delayed (24-month) booster dose.

conclusionsA single dose of the nonavalent HPV vaccine induced persistent and stable HPV16 and HPV18 antibody responses up to 24 months. This study contributes important immunogenicity data to inform feasibility of the single dose HPV vaccination paradigm. Further research is needed to assess the long-term antibody stability and individual clinical and public health benefit of the single dose schedule.

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesAntibodies, ViralAntibody FormationChildFemaleHuman papillomavirus 16Human papillomavirus 18HumansMaleAntibodies, ViralPapillomavirus Vaccines

Identifiers

PMID37317810
PMCPMC10312231
OpenAlexW4380730776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.